Abstract presented at EHA2022 describing preliminary data from a phase 1 study with the novel BCL2 inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with B-cell malignancies.
Abstract presented at EHA2022 describing preliminary safety and efficacy of BGB-11417, a potent
and selective BCL2 inhibitor, in patients with acute myeloid leukemia (AML).
The Satellite Symposium at ESH CLL was chaired by Prof Pierre Feugier joined by Prof Federico Pea, Dr Othman Al-Sawaf and Prof Wojciech Jurczak. They discuss managing and treating both treatment naïve (TN) and relapsed/refractory (R/R) CLL patients.
Preliminary safety and efficacy data of the phase 1a/1b trial of BGB-11417 (BCL2 inhibitor) with or without zanubrutinib in patients with relapsed/refractory B cell malignancies.
